Potential biomarker may contribute to personalized treatments
Until recently, medical treatment has largely been one-size-fits-all, with doctors unable to separate patients into distinct groups that might benefit more or less from a particular approach. However, researchers are increasingly finding that individuals with the same disease can differ markedly in ways that might one day influence their care. A recent IRP study has identified a particular molecule that may have just such an impact for patients with damaged lungs.
Virtually all parents would agree that having kids is a massive undertaking, and not just after they’re born. Many couples struggle to conceive, and each year thousands of American women experience complications when giving birth. With the help of the NIH’s state-of-the-art supercomputer, Biowulf, IRP senior investigator Rajeshwari Sundaram, Ph.D., develops and refines statistical tools that can guide prospective parents and their doctors through these challenges.
While many people think staving off aging means drinking seaweed smoothies and swallowing fish oil supplements, the key to extending life increasingly appears to be not putting things in our mouths. In yet another example of the anti-aging powers of eating less — what scientists call caloric restriction — IRP researchers have identified the specific aging-induced cellular and molecular changes in arteries that are curbed by substantially reducing calorie intake.
For Americans and others living outside the tropics, a mosquito bite is nothing more than an itchy inconvenience, but for billions of others, it can lead to a life-or-death battle with malaria. In some cases, the illness can wreak havoc on the brain. A new IRP study has used magnetic resonance imaging (MRI) technology to demonstrate that an investigational therapy can reverse that damage in mice.
Science is a process of trial and error. Most successful research publications are preceded by at least a few false starts and perhaps weeks or even months of tinkering to get experiments to work. For IRP senior investigator Carson Chow, Ph.D., this process of testing and throwing out one potential solution after another is an essential part of his research, so much so that he may go through thousands of iterations before arriving at one that works. However, rather than test each approach himself, he leverages the IRP’s considerable computing power to considerably accelerate the process of sorting the wheat from the chaff.
The more scientists have learned about the community of benign bacteria inside our bodies, known as the microbiome, the more effort they have put into recruiting it in the fight against disease. What’s more, scientists occasionally discover that treatments long thought to work completely independently of our native microbes also relieve symptoms by interacting with them. New IRP research into the most commonly used medication for type 2 diabetes has led to just such a revelation by demonstrating that its benefits stem in part from its ability to kill off a particular species of bacteria in the human digestive tract.
The human genome comprises roughly three billion base pairs and around 20,000 protein-coding genes, according to recent estimates. That’s a lot of information crammed into the tiny nucleus of a cell, and it doesn’t even include the many genes that do not produce a protein or the fact that most genes come in multiple flavors that vary in different individuals. Add to that the phenomenon of an identical gene being either more or less active in two different people and you can quickly end up with genomic datasets that would overload nearly any computer. Fortunately for IRP senior investigator Daniel Levy, M.D., the NIH IRP has one of the few computer systems in the world that can handle this mountain of information.
In 2016, more than one in twenty American adults and one in ten adolescents experienced at least one major depressive episode. For nearly 45,000 of these individuals, their condition was severe enough that it led them to take their own lives. Unfortunately, the medications currently available to treat depression are not always effective and can take up to six weeks to substantially reduce symptoms.
To improve treatment and accelerate symptom relief, IRP senior investigator Carlos Zarate Jr., M.D., is working towards the development of new medications for depression, along with the identification of new drug targets and objective measures called biomarkers that yield information about how a patient is responding to treatment. In recent years, his lab has extensively investigated and assessed the effects of the anesthetic drug ketamine on depression and suicidal thoughts. Many of the patients in his trials have had marked and rapid responses to ketamine, sometimes within a single day or just a couple of hours.
On Tuesday, November 13, Dr. Zarate participated in a Reddit “Ask Me Anything” (AMA) to answer questions from the public about the way depression is currently treated and the latest efforts to develop cutting-edge therapies for the condition. Read on for some of the most interesting exchanges that took place or check out the full AMA on Reddit.
The three-quarters of Americans who own a smartphone use them not just for communicating but also keeping a calendar, playing games, scouring the Internet for funny cat memes, and — soon — maybe even evaluating their neurological health. A new study conducted by IRP and University of Maryland researchers has confirmed the potential of smartphone apps for gauging symptoms of the neurological disease multiple sclerosis.
Every good gardener knows the importance of fertilizing the soil before planting seeds, and evidence is accumulating that a similar concept applies to the human body when it comes to experimental stem cell therapies. A new IRP studyhas uncovered how a medical technology called pulsed-focused ultrasound boosts the healing potency of a particular stem cell treatment.
